Adaptive Patient Population Selection Design in Clinical Trials

Statistics in Biopharmaceutical Research

Volumn 4, Issue 1, 2012, Pages 86-99

  Quan, Hui ^a   Zhou, Dongli ^b   Mancini, Pierre ^a   He, Yi ^c   Koch, Gary ^d  

^a SANOFI   (France)

^b FOREST RESEARCH INSTITUTE   (United States)

^c EISAI INC   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

Closed step down testing procedure; Conditional power; Sample size re estimation; Trial simulation; Weighted combination test

Indexed keywords

EID: 84865049147     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2011.633874     Document Type: Article

References (16)

1. Bauer, P. and Kohne, K. 1994. Evaluation of Experiments with Adaptive Interim Analyses. Biometrics, 50: 1029-1041.
2. Bauer, P. and Posch, M. 2004. Letter to the Editor: Modification of the Sample Size and the Schedule of Interim Analyses in Survival Trials Based on Data Inspections. Statistics in Medicine, 23: 1333-1335.
3. Brannath, W. and Bauer, P. 2004. Optimal Conditional Error Functions for the Control of Conditional Power. Biometrics, 60: 715-723.
4. Brannath, W., Koenig, F. and Bauer, P. 2006. Estimation in Flexible Two Stage Designs. Statistics in Medicine, 25: 3366-3381.
5. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M. and Racine-Poon, A. 2009. Confirmatory Adaptive Designs With Bayesian Decision Tools for a Targeted Therapy in Oncology. Statistics in Medicine, 28: 1445-1463.
6. Bretz, F., Schmidli, H., Koenig, F., Racine, A. and Maurer, W. 2006. Confirmatory Seamless Phase II/III Clinical Trials With Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 48: 623-634.
7. Cui, L., Hung, H. M. and Wang, S. J. 1999. Modification of Sample Size in Group Sequential Clinical Trials. Biometrics, 55: 853-857.
8. FDA Draft Guidance for Industry. 2010. Adaptive Design Clinical Trial for Drugs and Biologics, Silver Spring, MD: U.S. FDA.
9. Koch, G. 1997. Discussion of "p-Value Adjustments for Subgroup Analyses. Journal of Biopharmaceutical Statistics, 7: 323-331.
10. Lehmacher, W. and Wassmer, G. 1999. Adaptive Sample Size Calculations in Group Sequential Trials. Biometrics, 55: 1286-1290.
11. Lokhnygina, Y. and Tsiatis, A. 2008. Optimal Two-Stage Group-Sequential Designs. Journal of Statistical Planning and Inference, 138: 489-499.
12. Schafer, H. and Muller, H. H. 2001. Modification of the Sample Size and the Schedule of Interim Analyses in Survival Trials Based on Data Inspections. Statistics in Medicine, 20: 3741-3751.
13. Shen, Y. and Cai, J. 2003. Sample Size Reestimation for Clinical Trials With Censored Survival Data. Journal of American Statistical Association, 98: 418-426.
14. Shih, W. J., Quan, H. and Li, G. 2004. Two-Stage Adaptive Strategy for Superiority and Non-Inferiority Hypotheses in Active Controlled Clinical Trials. Statistics in Medicine, 23: 2781-2798.
15. Wang, S. J., Hung, H. M. and O'Neill, R. 2009. Adaptive Patient Enrichment Design in Therapeutic Trials. Biometrical Journal, 51: 358-374.
16. Wassmer, G. 2006. Planning and Analyzing Adaptive Group Sequential Survival Trials. Biometrical Journal, 48: 714-729.